CLOV’s options market pricing reflects expectations of short-term volatility. Forecast probability models predict a 60% chance of testing the $1.65 level within two months. Health insurance company Clover Health (NASDAQ:CLOV) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 34.1% year on year to $477.6 million. Its GAAP loss of $0.02 per share was in line with analysts’ consensus estimates. $CLOV insiders have traded $CLOV stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales. CLOV stock forecast, based on blended fundamental and technical models, anticipates sustained trading above $1.50 if Q3 revenue beats consensus by at least 5%, reinforcing positive momentum.
